Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor
    2.
    发明授权
    Peptides recognized by melanoma-specific cytotoxic lymphocytes, and uses therefor 失效
    由黑素瘤特异性细胞毒性淋巴细胞识别的肽及其用途

    公开(公告)号:US06660276B1

    公开(公告)日:2003-12-09

    申请号:US08234784

    申请日:1994-04-29

    IPC分类号: A61K3900

    摘要: The instant disclosure identifies and synthesizes peptide residues initially isolated from a melanoma cell line. The peptides are capable of reconstituting an epitope recognized by tumor specific CTL. Some of the sequences are homologous with proteins identified as pMEL17, tyrosinase and cofilin. The present invention provides for the treatment of melanoma patients using synthetic peptides that reconstitute epitopes for melanoma specific CTL. In another embodiment the peptides are used as vaccines for imparting immunity. Alternatively, in one embodiment the peptides may be used to bind to antigen presenting cells in a method for providing specific antigenic stimulation of CTL. The instant invention provides CTL cell lines capable of recognizing reconstituted HLA-A2.1 epitopes and their use in methods of adoptive immunotherapy. The invention additionally provides for genes encoding for peptides capable of reconstituting epitopes recognized by tumor specific CTL and their use as vaccines in the prevention and management of melanoma. A splitter is also disclosed to identify active peptides.

    摘要翻译: 本公开确定并合成最初从黑素瘤细胞系分离的肽残基。 这些肽能够重组由肿瘤特异性CTL识别的表位。 一些序列与鉴定为pMEL17,酪氨酸酶和cofilin的蛋白质同源。 本发明提供使用重构黑色素瘤特异性CTL表位的合成肽治疗黑素瘤患者。 在另一个实施方案中,肽用作赋予免疫力的疫苗。 或者,在一个实施方案中,肽可以用于在用于提供CTL的特异性抗原刺激的方法中与抗原呈递细胞结合。 本发明提供能够识别重组的HLA-A2.1表位的CTL细胞系及其在过继性免疫治疗方法中的用途。 本发明另外提供编码能够重组由肿瘤特异性CTL识别的表位的肽的基因及其在预防和治疗黑素瘤中作为疫苗的用途。 还公开了一种分离器来鉴定活性肽。